PHAR logo

Pharming Group NV (PHAR)

Profile

Full Name

Pharming Group N.V.

Ticker Symbol

PHAR

Exchange

NASDAQ

Country

Netherlands

IPO

December 23, 2020

Indexes

Not included

Employees

404

Key Details

Price

$8.49(+5.46%)

Market cap

$580.61M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$297.20M(+21.15% YoY)

Annual EPS

-$0.18(-12.50% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 21, 25 HC Wainwright & Co.
Buy
Mar 20, 25 HC Wainwright & Co.
Buy
Mar 14, 25 Oppenheimer
Outperform
Mar 14, 25 HC Wainwright & Co.
Buy
Dec 17, 24 HC Wainwright & Co.
Buy
Dec 16, 24 HC Wainwright & Co.
Buy
Dec 11, 24 HC Wainwright & Co.
Buy
Dec 9, 24 Jefferies
Buy
Oct 28, 24 Oppenheimer
Outperform
Oct 24, 24 HC Wainwright & Co.
Buy

Institutional Ownership

  • What is the ticker symbol for Pharming Group NV?
  • Does Pharming Group NV pay dividends?
  • What sector is Pharming Group NV in?
  • What industry is Pharming Group NV in?
  • What country is Pharming Group NV based in?
  • When did Pharming Group NV go public?
  • Is Pharming Group NV in the S&P 500?
  • Is Pharming Group NV in the NASDAQ 100?
  • Is Pharming Group NV in the Dow Jones?
  • When was Pharming Group NV's last earnings report?
  • When does Pharming Group NV report earnings?
  • Should I buy Pharming Group NV stock now?

What is the ticker symbol for Pharming Group NV?

The ticker symbol for Pharming Group NV is NASDAQ:PHAR

Does Pharming Group NV pay dividends?

No, Pharming Group NV does not pay dividends

What sector is Pharming Group NV in?

Pharming Group NV is in the Healthcare sector

What industry is Pharming Group NV in?

Pharming Group NV is in the Biotechnology industry

What country is Pharming Group NV based in?

Pharming Group NV is headquartered in Netherlands

When did Pharming Group NV go public?

Pharming Group NV's initial public offering (IPO) was on December 23, 2020

Is Pharming Group NV in the S&P 500?

No, Pharming Group NV is not included in the S&P 500 index

Is Pharming Group NV in the NASDAQ 100?

No, Pharming Group NV is not included in the NASDAQ 100 index

Is Pharming Group NV in the Dow Jones?

No, Pharming Group NV is not included in the Dow Jones index

When was Pharming Group NV's last earnings report?

Pharming Group NV's most recent earnings report was on Mar 13, 2025

When does Pharming Group NV report earnings?

The next expected earnings date for Pharming Group NV is May 8, 2025

Should I buy Pharming Group NV stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page